P
Last Price
52 Week Range
CA$0.09 - CA$0.33
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | CA$11.98M |
EV | CA$11.08M |
Shares Outstanding | 109.32M |
Beta | 0.77 |
Industry | Biotechnology |
Analyst Rating | - |
Analyst Target Price | - |
Number of Analysts | 0 |
P/E E | - |
P/Revenue E | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin E | - |
Net Profit Margin E | - |
ROE E | - |
ROCE | - |
DPS E | - |
Payout Ratio E | - |
Div. Yield E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
P
Pharmala Biotech Holdings Inc.
MDMA
Sector
Healthcare
Industry
Biotechnology
CEO
Kadysh, Nicholas
Employees
Website
pharmala.caIPO Date
2022-01-11
Headquarters
1055 West Georgia Street, P.O. Box 11117, Vancouver, British Columbia, V6E 4N7, Canada
The last closing price of Pharmala Biotech Holdings (MDMA) is CA$0.11, reflecting a +0.00% change from the prior session. Last updated: December 31, 2025 at 4:03 PM Eastern Time
Review the recent MDMA stock performance trends:Past 1 Month: Pharmala Biotech Holdings (MDMA) shares have +10.00%.Past 3 Months: The stock has -8.33%.Past 6 Months: MDMA shares have -4.35%. Last updated: December 31, 2025 at 11:42 PM Eastern Time
Over the last year, Pharmala Biotech Holdings (MDMA) has established a 52-week price range between a high of CA$0.33 and a low of CA$0.09. This metric is essential for assessing the stock's annual volatility. Last updated: December 31, 2025 at 11:42 PM Eastern Time
Pharmala Biotech Holdings (MDMA) is considered a medium volatility stock. It has a beta of 0.77, which means it typically moves 0.77 times as much as the broader market. Over the past 52 weeks, MDMA has traded within a CA$0.09 – CA$0.33 range. Last updated: December 31, 2025 at 11:42 PM Eastern Time
The current Pharmala Biotech Holdings (MDMA) market capitalization is approximately CA$11.98M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Pharmala Biotech Holdings's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:42 PM Eastern Time
Pharmala Biotech Holdings (MDMA) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CA$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.
Based on the latest available analyst coverage, Pharmala Biotech Holdings (MDMA) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: December 31, 2025 at 4:03 PM Eastern Time
Like other publicly traded stocks, Pharmala Biotech Holdings (MDMA) shares are bought and sold on stock exchanges such as CNSX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Pharmala Biotech Holdings (MDMA) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add MDMA to your watchlist.
Pharmala Biotech Holdings trades under the ticker symbol MDMA on the CNSX stock exchange. The ticker MDMA is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.